Compare CAPR & UTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAPR | UTI |
|---|---|---|
| Founded | 2005 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2011 | 2003 |
| Metric | CAPR | UTI |
|---|---|---|
| Price | $30.60 | $35.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $41.38 | $37.50 |
| AVG Volume (30 Days) | 921.3K | ★ 948.8K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.67 |
| EPS | N/A | ★ 0.23 |
| Revenue | $22,270,465.00 | ★ $835,616,000.00 |
| Revenue This Year | N/A | $10.15 |
| Revenue Next Year | $17,308.50 | $8.23 |
| P/E Ratio | ★ N/A | $151.83 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | $4.30 | $21.29 |
| 52 Week High | $40.37 | $38.02 |
| Indicator | CAPR | UTI |
|---|---|---|
| Relative Strength Index (RSI) | 66.95 | 63.18 |
| Support Level | $22.09 | $30.22 |
| Resistance Level | $40.37 | $35.68 |
| Average True Range (ATR) | 1.84 | 1.65 |
| MACD | 0.17 | 0.09 |
| Stochastic Oscillator | 92.68 | 64.75 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Universal Technical Institute Inc is an educational institution. It provides undergraduate degree, as well as certificate programs for technicians in the automotive, diesel, collision repair, motorcycle and marine fields. The company's reportable segment which includes Universal Technical Institute (UTI) and Concorde Career Colleges, Corporate. Majority of the revenue is generated from UTI segment which provides different kinds of degree and non-degree transportation and skilled trades technical training programs under brands such as Universal Technical Institute, Motorcycle Mechanics Institute, Marine Mechanics Institute and others. It also provides dealer technician training or instructor staffing services to manufacturers.